You searched for: reduktase (Danska - Engelska)

hmg- coa reduktase hæmmere:
hmg-coa reductase inhibitors:

hmg-coa- reduktase- hÆmmere
hmg-coa reductase inhibitors

mangel på enzymet nadph-reduktase.
deficiency in the enzyme nadph reductase.

interaktion med hmg-coa reduktase inhibitorer:
interaction with hmg-coa reductase inhibitors:

5, 10- metylen- tetrahydrofolat reduktase (mthfr),
5,10-methylene-tetrahydrofolate reductase (mthfr),

hmg- coa reduktase hæmmere simvastatin 20 mg 1250 en gang daglig
simvastatin 20 mg 1250 mg bid qd∞

boceprevir bliver primært metaboliseret af aldoketo-reduktase (akr).
boceprevir is primarily metabolized by aldoketo reductase (akr).

70% af hæmningen af hmg- coa- reduktase skyldes aktive metabolitter.
approximately 70% of circulating inhibitory activity for hmg-coa reductase is attributed to active metabolites.

hmg- coa reduktase hæmmerne lovastatin og simvastatin metaboliseres i udstrakt grad af cyp3a4.
the hmg-coa reductase inhibitors lovastatin and simvastatin are highly dependent on cyp3a4 for metabolism, thus concomitant use of agenerase with simvastatin or lovastatin is not recommended due to an increased risk of myopathy, including rhabdomyolysis.

som med andre hmg- coa reduktase hæmmere er der tendens til at bivirkninghyppigheden er dosisafhængig.
as with other hmg-coa reductase inhibitors, the incidence of adverse drug reactions tends to be dose dependent.

62% (55 til 78) totalt antal hmg co-a reduktase-hæmmere:
62% (55 to 78) total hmg co-a reductase inhibitors:

hvis behandling med hmg-coa reduktase hæmmere er indiceret, anbefales behandling med pravastatin eller fluvastatin.
if treatment with a hmg-coa reductase inhibitor is indicated, pravastatin or fluvastatin is recommended.

in vitrohæmmer orto -og parahydroxylerede metabolitter hmg-coa-reduktase i samme grad som atorvastatin.ca.
in vitro, inhibition of hmg-coa reductase by ortho-and parahydroxylated metabolites is equivalent to that of atorvastatin.

nyfødte har nedsat methb- reduktase- aktivitet, og kan derfor have større risiko for at udvikle methæmoglobinæmi.
neonates have diminished methb reductase activity and could therefore be at greater risk of developing methaemoglobinaemia.

da en øget koncentration af hmg-coa reduktase hæmmere kan forårsage myopati, herunder rhabdomyolyse, kan samtidig administration med agenerase ikke anbefales.
since increased concentrations of hmg-coa reductase inhibitors may cause myopathy, including rhabdomyolysis, the combination of these medicinal products with agenerase is not recommended.

halveringstiden for hæmmende aktivitet over for hmg-coa-reduktase som følge af aktive metabolitter er ca.20-30 timer.
the half-life of inhibitory activity for hmg-coa reductase is approximately 20 to 30 hours due to the contribution of active metabolites.

i kliniske undersøgelser viste samtidig administration af rapamune og hmg- coa reduktase - hæmmere og/ eller fibrater at være vel tolereret.
in clinical trials, the concomitant administration of rapamune and hmg-coa reductase inhibitors and/ or fibrates was well tolerated.

hvis behandling med en hmg-coa reduktase hæmmer er indiceret, anbefales pravastatin eller fluvastatin (se pkt.4. 5) .
if treatment with a hmg-coa reductase inhibitor is indicated, pravastatin or fluvastatin is recommended (see section 4.5) .

som med andre hmg- coa reduktase inhibitorer (statiner) er pravastatin blevet forbundet med anfald af myalgi, myopati, og meget sjældent, rhabdomyolyse.
as with others hmg-coa reductase inhibitors (statins), pravastatin has been associated with the onset of myalgia, myopathy and very rarely, rhabdomyolysis.

desuden hæmmer cdatp reduktasen af ribonukleotid, det enzym, der er ansvarlig for omdannelsen af ribonukleotider til deoxyriboneukleotider.
furthermore, cdatp inhibits ribonucleotide reductase, the enzyme responsible for the conversion of ribonucleotides into deoxyribonucleotides.